The life science industry is making moves in the digital health space. In fact, within the last two years Sanofi, Novartis and GSK have all recently inked deals with digital health companies.
However, the relationship between pharma companies and digital health has not always been infallible. This week Novartis division Sandoz broke ties with its digital therapeutic partner Pear Therapeutics. ...
Startups can have a difficult time striking a balance between the fast pace of tech culture and healthcare’s slow-and-steady validation culture.
In part, the culture clash is a West Coast-East Coast divide, with tech giants congregating for the most part in California and hospitals and pharma in the Northeast, according to a panel moderated by CNBC’s Christina Farr at the MassBio Digital Health...
Digital health is still somewhat of an enigma to many in the traditional world of pharma, but that is rapidly changing. As the use cases for digital tools continues to evolve, the life science world is starting to make a concerted effort to engage the new technologies.
This growing digital health ecosystem is now a major conversation point at MassBio, an organization dedicated to advancing the...
Virtual assistants and wearable technologies are starting to catch the pharma world’s attention. The industry is exploring how the new tools can be used in research, clinical trials and inpatient settings. However, obstacles including privacy compliance and data standards are still questions that the industry is grappling with, according to panelists at the MassBio forum on Using Clinical Data...
